QUARTERLY REPORT

Q3 2023 — Quarterly report

Q3 2023PDF · 29 pages176 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from 	to
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
41-1321939
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota
(Address of principal executive offices)
55343
(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. 	Yes  	No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). 	Yes  	No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	 	Accelerated filer  	Non-accelerated filer 	
Smaller reporting company  	Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 	Yes  	No 
As of October 31, 2023, there were 924,925,293 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

-- 1 of 29 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited)............................................................................................................... 	1
Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 ...................................... 	1
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022.... 	2
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2023
and 2022 ........................................................................................................................................ 	3
Condensed Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2023 and
2022.............................................................................................................................................. 	4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 ................ 	6
Notes to the Condensed Consolidated Financial Statements............................................................................... 	7
1. 	Basis of Presentation ....................................................................................................................... 	7
2. 	Investments .................................................................................................................................. 	8
3. 	Fair Value .................................................................................................................................... 	10
4. 	Medical Costs Payable ..................................................................................................................... 	11
5. 	Short-Term Borrowings and Long-Term Debt......................................................................................... 	11
6. 	Dividends .................................................................................................................................... 	12
7. 	Commitments and Contingencies ........................................................................................................ 	12
8. 	Business Combinations .................................................................................................................... 	13
9. 	Segment Financial Information........................................................................................................... 	14
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations ......................................... 	16
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 	24
Item 4. 	Controls and Procedures ......................................................................................................................... 	24
Part II. Other Information
Item 1. 	Legal Proceedings ................................................................................................................................ 	25
Item 1A. 	Risk Factors........................................................................................................................................ 	25
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities ............................. 	25
Item 5. 	Other Information................................................................................................................................. 	25
Item 6. 	Exhibits ............................................................................................................................................. 	26
Signatures ......................................................................................................................................................... 	27

-- 2 of 29 --

PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)
September 30,
2023
December 31,
2022
Assets
Current assets:
Cash and cash equivalents ................................................................................................... 	$ 	38,915 	$ 	23,365
Short-term investments ....................................................................................................... 	5,182 	4,546
Accounts receivable, net...................................................................................................... 	20,673 	17,681
Other current receivables, net ............................................................................................... 	17,752 	12,769
Assets under management.................................................................................................... 	3,616 	4,087
Prepaid expenses and other current assets ................................................................................. 	5,767 	6,621
Total current assets .................................................................................................................. 	91,905 	69,069
Long-term investments ............................................................................................................. 	45,474 	43,728
Property, equipment and capitalized software, net ............................................................................. 	11,070 	10,128
Goodwill .............................................................................................................................. 	101,703 	93,352
Other intangible assets, net......................................................................................................... 	15,200 	14,401
Other assets ........................................................................................................................... 	16,711 	15,027
Total assets........................................................................................................................... 	$ 	282,063 	$ 	245,705
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable ........................................................................................................ 	$ 	32,792 	$ 	29,056
Accounts payable and accrued liabilities .................................................................................. 	31,164 	27,715
Short-term borrowings and current maturities of long-term debt ...................................................... 	5,290 	3,110
Unearned revenues ............................................................................................................ 	15,311 	3,075
Other current liabilities ....................................................................................................... 	29,622 	26,281
Total current liabilities.............................................................................................................. 	114,179 	89,237
Long-term debt, less current maturities .......................................................................................... 	58,079 	54,513
Deferred income taxes .............................................................................................................. 	2,210 	2,769
Other liabilities....................................................................................................................... 	13,615 	12,839
Total liabilities ....................................................................................................................... 	188,083 	159,358
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests ............................................................................................. 	4,416 	4,897
Equity:
Preferred stock, $0.001 par value — 10 shares authorized; no shares issued or outstanding ..................... 	— 	—
Common stock, $0.01 par value — 3,000 shares authorized; 925 and 934 issued and outstanding ............. 	9 	9
Retained earnings.............................................................................................................. 	93,173 	86,156
Accumulated other comprehensive loss.................................................................................... 	(8,688) 	(8,393)
Nonredeemable noncontrolling interests................................................................................... 	5,070 	3,678
Total equity ........................................................................................................................... 	89,564 	81,450
Total liabilities, redeemable noncontrolling interests and equity ....................................................... 	$ 	282,063 	$ 	245,705
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
(in millions, except per share data) 	2023 	2022 	2023 	2022
Three Months Ended
September 30,
Nine Months Ended
September 30,
Revenues:
Premiums........................................................................................ 	$ 	72,339 	$ 	64,491 	$ 	217,599 	$ 	192,457
Products ......................................................................................... 	10,354 	9,190 	31,272 	28,026
Services.......................................................................................... 	8,671 	6,700 	25,414 	19,717
Investment and other income ................................................................ 	997 	513 	2,910 	1,175
Total revenues ........................................................................................ 	92,361 	80,894 	277,195 	241,375
Operating costs:
Medical costs ................................................................................... 	59,550 	52,635 	179,663 	157,251
Operating costs ................................................................................. 	13,855 	11,663 	41,289 	34,773
Cost of products sold .......................................................................... 	9,423 	8,306 	28,576 	25,389
Depreciation and amortization ............................................................... 	1,007 	828 	2,998 	2,418
Total operating costs ................................................................................ 	83,835 	73,432 	252,526 	219,831
Earnings from operations......................................................................... 	8,526 	7,462 	24,669 	21,544
Interest expense ...................................................................................... 	(834) 	(516) 	(2,416) 	(1,416)
Earnings before income taxes.................................................................... 	7,692 	6,946 	22,253 	20,128
Provision for income taxes ......................................................................... 	(1,654) 	(1,562) 	(4,784) 	(4,397)
Net earnings.......................................................................................... 	6,038 	5,384 	17,469 	15,731
Earnings attributable to noncontrolling interests................................................ 	(197) 	(122) 	(543) 	(372)
Net earnings attributable to UnitedHealth Group common shareholders............. 	$ 	5,841 	$ 	5,262 	$ 	16,926 	$ 	15,359
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic ............................................................................................. 	$ 	6.31 	$ 	5.63 	$ 	18.20 	$ 	16.37
Diluted ........................................................................................... 	$ 	6.24 	$ 	5.55 	$ 	18.01 	$ 	16.15
Basic weighted-average number of common shares outstanding ........................ 	926 	935 	930 	938
Dilutive effect of common share equivalents ................................................. 	10 	13 	10 	13
Diluted weighted-average number of common shares outstanding ..................... 	936 	948 	940 	951
Anti-dilutive shares excluded from the calculation of dilutive effect of common share
equivalents ......................................................................................... 	6 	3 	6 	3
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
(in millions) 	2023 	2022 	2023 	2022
Three Months Ended
September 30,
Nine Months Ended
September 30,
Net earnings................................................................................................ 	$ 	6,038 	$ 	5,384 	$ 	17,469 	$ 	15,731
Other comprehensive loss:
Gross unrealized losses on investment securities during the period ................... 	(893) 	(1,471) 	(684) 	(4,825)
Income tax effect............................................................................... 	204 	340 	156 	1,109
Total unrealized losses, net of tax..................................................... 	(689) 	(1,131) 	(528) 	(3,716)
Gross reclassification adjustment for net realized losses (gains) included in net
earnings....................................................................................... 	7 	138 	(27) 	134
Income tax effect............................................................................... 	(2) 	(32) 	6 	(31)
Total reclassification adjustment, net of tax ......................................... 	5 	106 	(21) 	103
Total foreign currency translation (losses) gains ......................................... 	(354) 	(331) 	254 	(89)
Other comprehensive loss .......................................................................... 	(1,038) 	(1,356) 	(295) 	(3,702)
Comprehensive income ................................................................................... 	5,000 	4,028 	17,174 	12,029
Comprehensive income attributable to noncontrolling interests.................................... 	(197) 	(122) 	(543) 	(372)
Comprehensive income attributable to UnitedHealth Group common shareholders ..... 	$ 	4,803 	$ 	3,906 	$ 	16,631 	$ 	11,657
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Three months ended September 30,
(in millions) 	Shares Amount
Additional
Paid-In
Capital Retained
Earnings
Net Unrealized
Losses
on Investments
Foreign
Currency
Translation
Losses
Nonredeemable
Noncontrolling
Interests Total
Equity
Common Stock
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023 ................... 	927 $ 	9 $ 	— $ 	89,994 $ 	(2,643) $ 	(5,007) $ 	5,015 $ 87,368
Net earnings .................................. 	5,841 	149 	5,990
Other comprehensive loss .................. 	(684) 	(354) 	(1,038)
Issuances of common stock, and related
tax effects .................................. 	1 	— 	395 	395
Share-based compensation ................. 	235 	235
Common share repurchases ................ 	(3) 	— 	(588) 	(923) 	(1,511)
Cash dividends paid on common shares
($1.88 per share) .......................... 	(1,739) 	(1,739)
Redeemable noncontrolling interests fair
value and other adjustments............. 	(42) 	(42)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests ..................................... 	42 	42
Distribution to nonredeemable
noncontrolling interests .................. 	(136) 	(136)
Balance at September 30, 2023............ 	925 $ 	9 $ 	— $ 	93,173 $ 	(3,327) $ 	(5,361) $ 	5,070 $ 89,564
Balance at June 30, 2022 ................... 	935 $ 	10 $ 	— $ 	80,540 $ 	(2,165) $ 	(5,565) $ 	3,385 $ 76,205
Net earnings .................................. 	5,262 	99 	5,361
Other comprehensive loss .................. 	(1,025) 	(331) 	(1,356)
Issuances of common stock, and related
tax effects .................................. 	2 	— 	294 	294
Share-based compensation ................. 	163 	163
Common share repurchases ................ 	(2) 	— 	(462) 	(538) 	(1,000)
Cash dividends paid on common shares
($1.65 per share) .......................... 	(1,542) 	(1,542)
Redeemable noncontrolling interests fair
value and other adjustments............. 	5 	5
Acquisition and other adjustments of
nonredeemable noncontrolling
interests ..................................... 	32 	32
Distribution to nonredeemable
noncontrolling interests .................. 	(98) 	(98)
Balance at September 30, 2022............ 	935 $ 	10 $ 	— $ 	83,722 $ 	(3,190) $ 	(5,896) $ 	3,418 $ 78,064
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Nine months ended September 30,
(in millions) 	Shares Amount
Additional
Paid-In
Capital Retained
Earnings
Net Unrealized
(Losses) Gains
on Investments
Foreign
Currency
Translation
(Losses) Gains
Nonredeemable
Noncontrolling
Interests Total
Equity
Common Stock
Accumulated Other
Comprehensive
(Loss) Income
Balance at January 1, 2023 ................. 	934 $ 	9 $ 	— $ 	86,156 $ 	(2,778) $ 	(5,615) $ 	3,678 $ 81,450
Net earnings .................................. 	16,926 	401 	17,327
Other comprehensive (loss) income ...... 	(549) 	254 	(295)
Issuances of common stock, and related
tax effects .................................. 	4 	— 	963 	963
Share-based compensation ................. 	833 	833
Common share repurchases ................ 	(13) 	— 	(1,663) 	(4,886) 	(6,549)
Cash dividends paid on common shares
($5.41 per share) .......................... 	(5,023) 	(5,023)
Redeemable noncontrolling interests fair
value and other adjustments............. 	(133) 	(133)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests ..................................... 	1,339 	1,339
Distribution to nonredeemable
noncontrolling interests .................. 	(348) 	(348)
Balance at September 30, 2023............ 	925 $ 	9 $ 	— $ 	93,173 $ 	(3,327) $ 	(5,361) $ 	5,070 $ 89,564
Balance at January 1, 2022 ................. 	941 $ 	10 $ 	— $ 	77,134 $ 	423 $ 	(5,807) $ 	3,285 $ 75,045
Net earnings .................................. 	15,359 	281 	15,640
Other comprehensive loss .................. 	(3,613) 	(89) 	(3,702)
Issuances of common stock, and related
tax effects .................................. 	6 	— 	801 	801
Share-based compensation ................. 	639 	639
Common share repurchases ................ 	(12) 	— 	(1,679) 	(4,321) 	(6,000)
Cash dividends paid on common shares
($4.75 per share) .......................... 	(4,450) 	(4,450)
Redeemable noncontrolling interests fair
value and other adjustments............. 	239 	239
Acquisition and other adjustments of
nonredeemable noncontrolling
interests ..................................... 	135 	135
Distribution to nonredeemable
noncontrolling interests .................. 	(283) 	(283)
Balance at September 30, 2022............ 	935 $ 	10 $ 	— $ 	83,722 $ 	(3,190) $ 	(5,896) $ 	3,418 $ 78,064
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in millions) 	2023 	2022
Nine Months Ended
September 30,
Operating activities
Net earnings ............................................................................................................................... 	$ 	17,469 	$ 	15,731
Noncash items:
Depreciation and amortization ................................................................................................... 	2,998 	2,418
Deferred income taxes............................................................................................................. 	(494) 	(590)
Share-based compensation........................................................................................................ 	851 	675
Other, net ............................................................................................................................ 	(59) 	—
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable ............................................................................................................... 	(2,574) 	(2,563)
Other assets ......................................................................................................................... 	(2,358) 	(741)
Medical costs payable ............................................................................................................. 	3,837 	4,192
Accounts payable and other liabilities .......................................................................................... 	2,370 	1,416
Unearned revenues ................................................................................................................. 	12,221 	10,201
Cash flows from operating activities.................................................................................................. 	34,261 	30,739
Investing activities
Purchases of investments ............................................................................................................... 	(12,998) 	(14,183)
Sales of investments ..................................................................................................................... 	3,674 	5,376
Maturities of investments ............................................................................................................... 	6,474 	4,740
Cash paid for acquisitions, net of cash assumed .................................................................................... 	(8,389) 	(7,154)
Purchases of property, equipment and capitalized software....................................................................... 	(2,427) 	(1,936)
Other, net .................................................................................................................................. 	(721) 	50
Cash flows used for investing activities .............................................................................................. 	(14,387) 	(13,107)
Financing activities
Common share repurchases............................................................................................................. 	(6,500) 	(6,000)
Cash dividends paid...................................................................................................................... 	(5,023) 	(4,450)
Proceeds from common stock issuances.............................................................................................. 	1,039 	1,084
Repayments of long-term debt ......................................................................................................... 	(2,125) 	(2,100)
Proceeds from (repayments of) short-term borrowings, net ....................................................................... 	1,579 	(16)
Proceeds from issuance of long-term debt ........................................................................................... 	6,394 	5,922
Customer funds administered .......................................................................................................... 	2,037 	7,028
Other, net .................................................................................................................................. 	(1,774) 	(1,634)
Cash flows used for financing activities.............................................................................................. 	(4,373) 	(166)
Effect of exchange rate changes on cash and cash equivalents ................................................................... 	49 	4
Increase in cash and cash equivalents.............................................................................................. 	15,550 	17,470
Cash and cash equivalents, beginning of period ................................................................................. 	23,365 	21,375
Cash and cash equivalents, end of period ......................................................................................... 	$ 	38,915 	$ 	38,845
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 29 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is
a health care and well-being company with a mission to help people live healthier lives and help make the health system work
better for everyone. Our two distinct, yet complementary business platforms—Optum and UnitedHealthcare—are working to
help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the
individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end
condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures
required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the
Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual
audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read
together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and
Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the
SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments
necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill.
Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters
that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in
earnings in the period in which the estimate is adjusted.
Revenues — Products and Services
As of September 30, 2023 and December 31, 2022, accounts receivable related to products and services were $8.0 billion and
$7.1 billion, respectively. As of September 30, 2023, revenue expected to be recognized in any future year related to remaining
performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less,
contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance
obligations, was $11.8 billion, of which approximately half is expected to be recognized in the next three years.
7

-- 9 of 29 --

2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
September 30, 2023
Debt securities — available-for-sale:
U.S. government and agency obligations .................................................... 	$ 	5,739 	$ 	— 	$ 	(340) $ 	5,399
State and municipal obligations ............................................................... 	7,695 	1 	(643) 	7,053
Corporate obligations............................................................................ 	23,511 	5 	(1,857) 	21,659
U.S. agency mortgage-backed securities ..................................................... 	8,632 	— 	(1,158) 	7,474
Non-U.S. agency mortgage-backed securities ............................................... 	3,091 	— 	(324) 	2,767
Total debt securities — available-for-sale ......................................................... 	48,668 	6 	(4,322) 	44,352
Debt securities — held-to-maturity:
U.S. government and agency obligations .................................................... 	466 	— 	(10) 	456
State and municipal obligations ............................................................... 	28 	— 	(5) 	23
Corporate obligations............................................................................ 	188 	— 	— 	188
Total debt securities — held-to-maturity........................................................... 	682 	— 	(15) 	667
Total debt securities ................................................................................... 	$ 	49,350 	$ 	6 	$ 	(4,337) $ 	45,019
December 31, 2022
Debt securities — available-for-sale:
U.S. government and agency obligations .................................................... 	$ 	4,093 	$ 	1 	$ 	(285) $ 	3,809
State and municipal obligations ............................................................... 	7,702 	25 	(479) 	7,248
Corporate obligations............................................................................ 	23,675 	17 	(1,798) 	21,894
U.S. agency mortgage-backed securities ..................................................... 	7,379 	15 	(808) 	6,586
Non-U.S. agency mortgage-backed securities ............................................... 	3,077 	1 	(294) 	2,784
Total debt securities — available-for-sale ......................................................... 	45,926 	59 	(3,664) 	42,321
Debt securities — held-to-maturity:
U.S. government and agency obligations .................................................... 	578 	— 	(14) 	564
State and municipal obligations ............................................................... 	29 	— 	(3) 	26
Corporate obligations............................................................................ 	89 	— 	— 	89
Total debt securities — held-to-maturity........................................................... 	696 	— 	(17) 	679
Total debt securities ................................................................................... 	$ 	46,622 	$ 	59 	$ 	(3,681) $ 	43,000
The Company held $4.2 billion and $3.7 billion of equity securities as of September 30, 2023 and December 31, 2022,
respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments,
venture investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values.
Additionally, the Company’s investments included $1.4 billion and $1.5 billion of equity method investments in operating
businesses in the health care sector as of September 30, 2023 and December 31, 2022, respectively. The allowance for credit
losses on held-to-maturity securities at September 30, 2023 and December 31, 2022 was not material.
8

-- 10 of 29 --

The amortized cost and fair value of debt securities as of September 30, 2023, by contractual maturity, were as follows:
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Available-for-Sale 	Held-to-Maturity
Due in one year or less ................................................................................. 	$ 	5,372 	$ 	5,340 	$ 	375 	$ 	372
Due after one year through five years ............................................................... 	15,098 	14,183 	262 	255
Due after five years through ten years ............................................................... 	11,256 	9,898 	25 	24
Due after ten years ...................................................................................... 	5,219 	4,690 	20 	16
U.S. agency mortgage-backed securities ............................................................ 	8,632 	7,474 	— 	—
Non-U.S. agency mortgage-backed securities ...................................................... 	3,091 	2,767 	— 	—
Total debt securities .................................................................................... 	$ 	48,668 	$ 	44,352 	$ 	682 	$ 	667
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
Less Than 12 Months 	12 Months or Greater 	Total
September 30, 2023
Debt securities — available-for-sale:
U.S. government and agency obligations .......... 	$ 	2,023 	$ 	(34) $ 	2,081 	$ 	(306) $ 	4,104 	$ 	(340)
State and municipal obligations ..................... 	2,872 	(124) 	4,042 	(519) 	6,914 	(643)
Corporate obligations ................................. 	5,563 	(149) 	14,821 	(1,708) 	20,384 	(1,857)
U.S. agency mortgage-backed securities ........... 	2,562 	(140) 	4,867 	(1,018) 	7,429 	(1,158)
Non-U.S. agency mortgage-backed securities..... 	480 	(21) 	2,249 	(303) 	2,729 	(324)
Total debt securities — available-for-sale ............... 	$ 	13,500 	$ 	(468) $ 	28,060 	$ 	(3,854) $ 	41,560 	$ 	(4,322)
December 31, 2022
Debt securities — available-for-sale:
U.S. government and agency obligations .......... 	$ 	2,007 	$ 	(96) $ 	1,290 	$ 	(189) $ 	3,297 	$ 	(285)
State and municipal obligations ..................... 	4,630 	(288) 	1,178 	(191) 	5,808 	(479)
Corporate obligations ................................. 	13,003 	(893) 	6,637 	(905) 	19,640 	(1,798)
U.S. agency mortgage-backed securities ........... 	3,561 	(345) 	2,239 	(463) 	5,800 	(808)
Non-U.S. agency mortgage-backed securities..... 	1,698 	(128) 	976 	(166) 	2,674 	(294)
Total debt securities — available-for-sale ............... 	$ 	24,899 	$ 	(1,750) $ 	12,320 	$ 	(1,914) $ 	37,219 	$ 	(3,664)
The Company’s unrealized losses from debt securities as of September 30, 2023 were generated from approximately 37,000
positions out of a total of 41,000 positions. The Company believes that it will timely collect the principal and interest due on its
debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate
increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s
assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt
securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company
evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit
deterioration since purchase. As of September 30, 2023, the Company did not have the intent to sell any of the available-for-sale
debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for
credit losses on available-for-sale debt securities at September 30, 2023 and December 31, 2022 was not material.
9

-- 11 of 29 --

3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in
Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
September 30, 2023
Cash and cash equivalents ...................................................................... 	$ 	38,880 	$ 	35 	$ 	— 	$ 38,915
Debt securities — available-for-sale:
U.S. government and agency obligations .............................................. 	5,050 	349 	— 	5,399
State and municipal obligations ......................................................... 	— 	7,053 	— 	7,053
Corporate obligations...................................................................... 	15 	21,462 	182 	21,659
U.S. agency mortgage-backed securities ............................................... 	— 	7,474 	— 	7,474
Non-U.S. agency mortgage-backed securities......................................... 	— 	2,767 	— 	2,767
Total debt securities — available-for-sale ................................................... 	5,065 	39,105 	182 	44,352
Equity securities.................................................................................. 	2,231 	31 	70 	2,332
Assets under management ...................................................................... 	1,420 	2,094 	102 	3,616
Total assets at fair value ........................................................................ 	$ 	47,596 	$ 41,265 	$ 	354 	$ 89,215
Percentage of total assets at fair value........................................................ 	53% 	46% 	1% 	100%
December 31, 2022
Cash and cash equivalents ...................................................................... 	$ 	23,202 	$ 	163 	$ 	— 	$ 23,365
Debt securities — available-for-sale:
U.S. government and agency obligations .............................................. 	3,505 	304 	— 	3,809
State and municipal obligations ......................................................... 	— 	7,248 	— 	7,248
Corporate obligations...................................................................... 	7 	21,695 	192 	21,894
U.S. agency mortgage-backed securities ............................................... 	— 	6,586 	— 	6,586
Non-U.S. agency mortgage-backed securities......................................... 	— 	2,784 	— 	2,784
Total debt securities — available-for-sale ................................................... 	3,512 	38,617 	192 	42,321
Equity securities.................................................................................. 	2,043 	35 	70 	2,148
Assets under management ...................................................................... 	1,788 	2,203 	96 	4,087
Total assets at fair value ........................................................................ 	$ 	30,545 	$ 41,018 	$ 	358 	$ 71,921
Percentage of total assets at fair value........................................................ 	42% 	57% 	1% 	100%
There were no transfers in or out of Level 3 financial assets or liabilities during the nine months ended September 30, 2023 or 2022.
10

-- 12 of 29 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
September 30, 2023
Debt securities — held-to-maturity ............................... 	$ 	593 	$ 	74 	$ 	— 	$ 	667 	$ 	682
Long-term debt and other financing obligations ................ 	$ 	— 	$ 	55,137 	$ 	— 	$ 	55,137 	$ 	60,769
December 31, 2022
Debt securities — held-to-maturity ............................... 	$ 	577 	$ 	102 	$ 	— 	$ 	679 	$ 	696
Long-term debt and other financing obligations ................ 	$ 	— 	$ 	53,626 	$ 	— 	$ 	53,626 	$ 	56,823
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were
no significant fair value adjustments for these assets and liabilities recorded during the nine months ended September 30, 2023
or 2022.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the nine months ended September 30:
(in millions) 	2023 	2022
Medical costs payable, beginning of period ...................................................................................... 	$ 	29,056 	$ 	24,483
Acquisitions............................................................................................................................ 	1 	177
Reported medical costs:
Current year...................................................................................................................... 	180,423 	157,601
Prior years........................................................................................................................ 	(760) 	(350)
Total reported medical costs ........................................................................................................ 	179,663 	157,251
Medical payments:
Payments for current year ..................................................................................................... 	(149,671) 	(130,788)
Payments for prior years....................................................................................................... 	(26,257) 	(22,059)
Total medical payments.............................................................................................................. 	(175,928) 	(152,847)
Medical costs payable, end of period.............................................................................................. 	$ 	32,792 	$ 	29,064
For the nine months ended September 30, 2023 and 2022, prior years’ medical cost reserve development included no individual
factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to
the Company of $22.7 billion and $20.0 billion at September 30, 2023 and December 31, 2022, respectively.
5. 	Short-Term Borrowings and Long-Term Debt
In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following:
(in millions, except percentages) 	Par Value
4.250% notes due January 2029 ....................................................................................................................... 	$ 	1,250
4.500% notes due April 2033 .......................................................................................................................... 	1,500
5.050% notes due April 2053 .......................................................................................................................... 	2,000
5.200% notes due April 2063 .......................................................................................................................... 	1,750
As of September 30, 2023, the Company had $2.6 billion of commercial paper outstanding, with a weighted-average annual
interest rate of 5.3%.
11

-- 13 of 29 --

For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K.
6. 	Dividends
In June 2023, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual
rate of $7.52 compared to $6.60 per share, which the Company had paid since June 2022. Declaration and payment of future
quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions
change.
The following table provides details of the Company’s dividend payments during the nine months ended September 30, 2023:
Payment Date 	Amount per Share 	Total Amount Paid
(in millions)
March 21 ............................................................................................................ 	$ 	1.65 	$ 	1,537
June 27............................................................................................................... 	1.88 	1,747
September 19 ....................................................................................................... 	1.88 	1,739
7. 	Commitments and Contingencies
Pending Acquisitions
As of September 30, 2023, the Company has entered into agreements to acquire companies in the health care sector, subject to
regulatory approval and other customary closing conditions. The total anticipated consideration required for these acquisitions,
excluding the payoff of acquired indebtedness, is approximately $5 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits
brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s
businesses, including management and administration of health benefit plans and other services. These matters include medical
malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits
coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the
matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel
legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early
stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate
the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the
Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the
U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the
Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities.
Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign
governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses
have been reviewed or are currently under review, including for, among other matters, compliance with coding and other
12

-- 14 of 29 --

requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk
adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by
health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the
Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15,
2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12,
2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss
the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the
court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without
prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
8. 	Business Combinations
During the nine months ended September 30, 2023, the Company completed several business combinations for total
consideration of $8.4 billion.
Acquired assets (liabilities) at acquisition date were:
(in millions)
Cash and cash equivalents ...................................................................................................................... 	$ 	104
Accounts receivable and other current assets ................................................................................................ 	587
Property, equipment and other long-term assets............................................................................................. 	573
Other intangible assets........................................................................................................................... 	1,800
Total identifiable assets acquired ........................................................................................................ 	3,064
Medical costs payable ........................................................................................................................... 	(1)
Accounts payable and other current liabilities............................................................................................... 	(551)
Other long-term liabilities....................................................................................................................... 	(661)
Total identifiable liabilities acquired .................................................................................................... 	(1,213)
Total net identifiable assets......................................................................................................... 	1,851
Goodwill ........................................................................................................................................... 	8,073
Redeemable noncontrolling interests .......................................................................................................... 	(121)
Nonredeemable noncontrolling interests...................................................................................................... 	(1,339)
Net assets acquired ................................................................................................................... 	$ 	8,464
The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various
business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent
liabilities, are finalized.
The acquisition date fair values and weighted-average useful lives assigned to intangible assets were:
(in millions, except years) Fair
Value
Weighted-
Average
Useful Life
Acquired finite-lived intangible assets:
Customer-related ......................................................................................................... $ 	223 	12 years
Trademarks and technology ............................................................................................ 	171 	5 years
Other ....................................................................................................................... 	42 	6 years
Total acquired finite-lived intangible assets ............................................................................... 	436 	9 years
Total acquired indefinite-lived intangible assets — operating licenses and certificates............................ 	1,364
Total acquired intangible assets ............................................................................................. $ 	1,800
13

-- 15 of 29 --

The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results
and the results of the corresponding operating segment as of the date of acquisition. Through September 30, 2023, acquired
entities’ impact on revenues and net earnings was not material.
Unaudited pro forma revenues and net earnings for the nine months ended September 30, 2023 and 2022, as if the business
combinations had occurred on January 1, 2022, were immaterial for both periods.
9. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more
information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. Total assets at Optum
Health increased to $86.9 billion as of September 30, 2023 compared to $69.0 billion as of December 31, 2022, including an
increase to goodwill from business combinations of $7.3 billion.
The following tables present reportable segment financial information:
(in millions) 	UnitedHealthcare Optum Health Optum Insight Optum Rx
Optum
Eliminations 	Optum
Corporate and
Eliminations Consolidated
Optum
Three Months Ended September 30,
2023
Revenues — unaffiliated customers:
Premiums .................................. $ 	66,709 	$ 	5,630 	$ 	— $ 	— $ 	— $ 5,630 $ 	— $ 	72,339
Products.................................... 	— 	61 	40 	10,253 	— 	10,354 	— 	10,354
Services .................................... 	2,550 	3,629 	1,938 	554 	— 	6,121 	— 	8,671
Total revenues — unaffiliated customers .. 	69,259 	9,320 	1,978 	10,807 	— 	22,105 	— 	91,364
Total revenues — affiliated customers ..... 	— 	14,227 	2,964 	17,999 	(961) 	34,229 	(34,229) 	—
Investment and other income................. 	594 	317 	35 	51 	— 	403 	— 	997
Total revenues .................................. $ 	69,853 	$ 	23,864 	$ 	4,977 $ 28,857 $ 	(961) $56,737 $ 	(34,229) $ 	92,361
Earnings from operations ..................... $ 	4,592 	$ 	1,568 	$ 	1,109 $ 	1,257 $ 	— $ 3,934 $ 	— $ 	8,526
Interest expense................................. 	— 	— 	— 	— 	— 	— 	(834) 	(834)
Earnings before income taxes ................ $ 	4,592 	$ 	1,568 	$ 	1,109 $ 	1,257 $ 	— $ 3,934 $ 	(834) $ 	7,692
Three Months Ended September 30,
2022
Revenues — unaffiliated customers:
Premiums .................................. $ 	59,375 	$ 	5,116 	$ 	— $ 	— $ 	— $ 5,116 $ 	— $ 	64,491
Products.................................... 	— 	2 	37 	9,151 	— 	9,190 	— 	9,190
Services .................................... 	2,435 	2,756 	1,067 	442 	— 	4,265 	— 	6,700
Total revenues — unaffiliated customers .. 	61,810 	7,874 	1,104 	9,593 	— 	18,571 	— 	80,381
Total revenues — affiliated customers ..... 	— 	10,302 	2,566 	15,592 	(800) 	27,660 	(27,660) 	—
Investment and other income................. 	185 	287 	23 	18 	— 	328 	— 	513
Total revenues .................................. $ 	61,995 	$ 	18,463 	$ 	3,693 $ 25,203 $ 	(800) $46,559 $ 	(27,660) $ 	80,894
Earnings from operations ..................... $ 	3,799 	$ 	1,575 	$ 	1,007 $ 	1,081 $ 	— $ 3,663 $ 	— $ 	7,462
Interest expense................................. 	— 	— 	— 	— 	— 	— 	(516) 	(516)
Earnings before income taxes ................ $ 	3,799 	$ 	1,575 	$ 	1,007 $ 	1,081 $ 	— $ 3,663 $ 	(516) $ 	6,946
14

-- 16 of 29 --

(in millions) 	UnitedHealthcare Optum Health Optum Insight Optum Rx
Optum
Eliminations 	Optum
Corporate and
Eliminations 	Consolidated
Optum
Nine Months Ended September 30,
2023
Revenues — unaffiliated customers:
Premiums............................... $ 	201,214 $ 	16,385 $ 	— $ 	— $ 	— $ 16,385 $ 	— $ 	217,599
Products ................................ 	— 	156 	119 	30,997 	— 	31,272 	— 	31,272
Services................................. 	7,689 	10,259 	5,859 	1,607 	— 	17,725 	— 	25,414
Total revenues — unaffiliated
customers.................................. 	208,903 	26,800 	5,978 	32,604 	— 	65,382 	— 	274,285
Total revenues — affiliated customers .. 	— 	42,947 	8,089 	52,174 	(2,713) 	100,497 	(100,497) 	—
Investment and other income ............. 	1,649 	1,038 	80 	143 	— 	1,261 	— 	2,910
Total revenues ............................... $ 	210,552 $ 	70,785 $ 	14,147 $ 84,921 $ (2,713) $167,140 $ (100,497) $ 	277,195
Earnings from operations .................. $ 	13,293 $ 	4,869 $ 	2,984 $ 	3,523 $ 	— $ 11,376 $ 	— $ 	24,669
Interest expense ............................. 	— 	— 	— 	— 	— 	— 	(2,416) 	(2,416)
Earnings before income taxes............. $ 	13,293 $ 	4,869 $ 	2,984 $ 	3,523 $ 	— $ 11,376 $ 	(2,416) $ 	22,253
Nine Months Ended September 30,
2022
Revenues — unaffiliated customers:
Premiums............................... $ 	178,680 $ 	13,777 $ 	— $ 	— $ 	— $ 13,777 $ 	— $ 	192,457
Products ................................ 	— 	14 	135 	27,877 	— 	28,026 	— 	28,026
Services................................. 	7,492 	8,054 	3,075 	1,096 	— 	12,225 	— 	19,717
Total revenues — unaffiliated
customers.................................. 	186,172 	21,845 	3,210 	28,973 	— 	54,028 	— 	240,200
Total revenues — affiliated customers .. 	— 	30,355 	6,885 	44,921 	(1,941) 	80,220 	(80,220) 	—
Investment and other income ............. 	523 	528 	99 	25 	— 	652 	— 	1,175
Total revenues ............................... $ 	186,695 $ 	52,728 $ 	10,194 $ 73,919 $ (1,941) $134,900 $ 	(80,220) $ 	241,375
Earnings from operations .................. $ 	11,447 $ 	4,340 $ 	2,693 $ 	3,064 $ 	— $ 10,097 $ 	— $ 	21,544
Interest expense ............................. 	— 	— 	— 	— 	— 	— 	(1,416) 	(1,416)
Earnings before income taxes............. $ 	11,447 $ 	4,340 $ 	2,693 $ 	3,064 $ 	— $ 10,097 $ 	(1,416) $ 	20,128
15

-- 17 of 29 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2022 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,
“Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms
“UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of
Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking
statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2022 10-K
and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make
the health system work better for everyone. Our two distinct, yet complementary business platforms—Optum and
UnitedHealthcare—are working to help build a modern, high-performing health system through improved access, affordability,
outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
• 	Optum Health;
• 	Optum Insight;
• 	Optum Rx; and
• 	UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and
UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2022 10-K and additional information on our segments
can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I,
Item 1 of this report.
Business Trends
Our businesses participate in the United States, South America and certain other international health markets. We expect overall
spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement,
regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market
growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could
impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs,
including medical cost trends, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of
the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and
environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and
similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.
16

-- 18 of 29 --

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect
broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market
due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs.
During the third quarter we continued to observe increased care patterns, primarily related to outpatient procedures for seniors,
consistent with the levels observed in the second quarter, and which may continue in future periods. We endeavor to mitigate
those increases by engaging physicians and consumers with information and helping them make clinically sound choices, with
the objective of helping them achieve quality, affordable care.
Medicaid Redeterminations. The majority of states have resumed Medicaid redeterminations, which have impacted the number
of people served through our Medicaid offerings, partially offset by an increase in consumers served through our commercial
offerings as we endeavor to ensure that people and families have continued access to benefits.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices over the years have at times resulted in industry base rates well
below industry forward medical trend. For example, the Final Notice for 2024 rates resulted in an industry base rate decrease,
well short of what is an increasing industry forward medical cost trend, creating continued pressure in the Medicare Advantage
program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health
status and care resource needs, will result in reduced funding and potentially benefits for people, especially those with some of
the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures
and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make
changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the
member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on
a county-by-county basis where we will offer Medicare Advantage plans.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select third quarter 2023 year-over-year operating comparisons to third quarter 2022 and other
financial results.
• 	Consolidated revenues grew 14%, UnitedHealthcare revenues grew 13% and Optum revenues grew 22%.
• 	UnitedHealthcare served 1.5 million more people, driven by growth across each of our businesses.
• 	Consolidated earnings from operations of $8.5 billion compared to $7.5 billion last year, including growth of 21% at
UnitedHealthcare and 7% at Optum.
• 	Diluted earnings per common share were $6.24.
• 	Cash flows from operations for the nine months ended September 30, 2023 were $34.3 billion.
• 	Return on equity was 28.0%.
17

-- 19 of 29 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data) 	2023 	2022 	2023 vs. 2022 	2023 	2022 	2023 vs. 2022
Three Months Ended
September 30,
Increase/
(Decrease)
Nine Months Ended
September 30,
Increase/
(Decrease)
Revenues:
Premiums........................................... 	$ 	72,339 	$ 	64,491 	$ 	7,848 	12% $ 217,599 	$ 192,457 	$ 	25,142 	13%
Products ............................................ 	10,354 	9,190 	1,164 	13 	31,272 	28,026 	3,246 	12
Services............................................. 	8,671 	6,700 	1,971 	29 	25,414 	19,717 	5,697 	29
Investment and other income ................... 	997 	513 	484 	94 	2,910 	1,175 	1,735 	148
Total revenues ........................................... 	92,361 	80,894 	11,467 	14 	277,195 	241,375 	35,820 	15
Operating costs:
Medical costs ...................................... 	59,550 	52,635 	6,915 	13 	179,663 	157,251 	22,412 	14
Operating costs .................................... 	13,855 	11,663 	2,192 	19 	41,289 	34,773 	6,516 	19
Cost of products sold ............................. 	9,423 	8,306 	1,117 	13 	28,576 	25,389 	3,187 	13
Depreciation and amortization.................. 	1,007 	828 	179 	22 	2,998 	2,418 	580 	24
Total operating costs ................................... 	83,835 	73,432 	10,403 	14 	252,526 	219,831 	32,695 	15
Earnings from operations .............................. 	8,526 	7,462 	1,064 	14 	24,669 	21,544 	3,125 	15
Interest expense ......................................... 	(834) 	(516) 	(318) 	62 	(2,416) 	(1,416) 	(1,000) 	71
Earnings before income taxes......................... 	7,692 	6,946 	746 	11 	22,253 	20,128 	2,125 	11
Provision for income taxes ............................ 	(1,654) 	(1,562) 	(92) 	6 	(4,784) 	(4,397) 	(387) 	9
Net earnings ............................................. 	6,038 	5,384 	654 	12 	17,469 	15,731 	1,738 	11
Earnings attributable to noncontrolling interests... 	(197) 	(122) 	(75) 	61 	(543) 	(372) 	(171) 	46
Net earnings attributable to UnitedHealth Group
common shareholders ............................... 	$ 	5,841 	$ 	5,262 	$ 	579 	11% $ 	16,926 	$ 	15,359 	$ 	1,567 	10%
Diluted earnings per share attributable to
UnitedHealth Group common shareholders ..... 	$ 	6.24 	$ 	5.55 	$ 	0.69 	$ 	18.01 	$ 	16.15 	$ 	1.86
Medical care ratio (a) .................................. 	82.3% 	81.6% 	0.7% 	82.6% 	81.7% 	0.9%
Operating cost ratio..................................... 	15.0 	14.4 	0.6 	14.9 	14.4 	0.5
Operating margin ....................................... 	9.2 	9.2 	— 	8.9 	8.9 	—
Tax rate ................................................... 	21.5 	22.5 	(1.0) 	21.5 	21.8 	(0.3)
Net earnings margin (b)................................ 	6.3 	6.5 	(0.2) 	6.1 	6.4 	(0.3)
Return on equity (c) .................................... 	28.0% 	28.5% 	(0.5)% 	27.7% 	28.1% 	(0.4)%
(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity.
Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at
the end of each of the quarters in the year presented.
2023 RESULTS OF OPERATIONS COMPARED TO 2022 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in the number of people served through Medicare Advantage and
Medicaid, pricing trends and growth across the Optum businesses. Revenues also increased due to increased investment income,
primarily driven by increased interest rates.
18

-- 20 of 29 --

Medical Costs and MCR
Medical costs increased primarily due to growth in people served through Medicare Advantage and Medicaid. The MCR
increased as a result of elevated care activity, primarily relating to outpatient care for seniors, and business mix.
Operating Cost Ratio
The operating cost ratio increased primarily due to business mix and investments to support future growth, partially offset by
continued productivity advances.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people
served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted
scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, including the level and scope of services provided to
people, and pricing trends when comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
(in millions, except percentages) 	2023 	2022 	2023 vs. 2022 	2023 	2022 	2023 vs. 2022
Three Months Ended
September 30,
Increase/
(Decrease)
Nine Months Ended
September 30,
Increase/
(Decrease)
Revenues
UnitedHealthcare ...................................... 	$ 	69,853 	$ 	61,995 	$ 	7,858 	13% $ 	210,552 	$ 186,695 	$ 	23,857 	13%
Optum Health .................................... 	23,864 	18,463 	5,401 	29 	70,785 	52,728 	18,057 	34
Optum Insight.................................... 	4,977 	3,693 	1,284 	35 	14,147 	10,194 	3,953 	39
Optum Rx ........................................ 	28,857 	25,203 	3,654 	14 	84,921 	73,919 	11,002 	15
Optum eliminations ............................. 	(961) 	(800) 	(161) 	20 	(2,713) 	(1,941) 	(772) 	40
Optum ................................................... 	56,737 	46,559 	10,178 	22 	167,140 	134,900 	32,240 	24
Eliminations............................................ 	(34,229) 	(27,660) 	(6,569) 	24 	(100,497) 	(80,220) 	(20,277) 	25
Consolidated revenues................................ 	$ 	92,361 	$ 	80,894 	$ 11,467 	14% $ 	277,195 	$ 241,375 	$ 	35,820 	15%
Earnings from operations
UnitedHealthcare ...................................... 	$ 	4,592 	$ 	3,799 	$ 	793 	21% $ 	13,293 	$ 	11,447 	$ 	1,846 	16%
Optum Health .................................... 	1,568 	1,575 	(7) 	— 	4,869 	4,340 	529 	12
Optum Insight.................................... 	1,109 	1,007 	102 	10 	2,984 	2,693 	291 	11
Optum Rx ........................................ 	1,257 	1,081 	176 	16 	3,523 	3,064 	459 	15
Optum ................................................... 	3,934 	3,663 	271 	7 	11,376 	10,097 	1,279 	13
Consolidated earnings from operations ............ 	$ 	8,526 	$ 	7,462 	$ 	1,064 	14% $ 	24,669 	$ 	21,544 	$ 	3,125 	15%
Operating margin
UnitedHealthcare ...................................... 	6.6% 	6.1% 	0.5% 	6.3% 	6.1% 	0.2%
Optum Health .................................... 	6.6 	8.5 	(1.9) 	6.9 	8.2 	(1.3)
Optum Insight.................................... 	22.3 	27.3 	(5.0) 	21.1 	26.4 	(5.3)
Optum Rx ........................................ 	4.4 	4.3 	0.1 	4.1 	4.1 	—
Optum ................................................... 	6.9 	7.9 	(1.0) 	6.8 	7.5 	(0.7)
Consolidated operating margin ..................... 	9.2% 	9.2% 	—% 	8.9% 	8.9% 	—%
19

-- 21 of 29 --

UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
(in millions, except percentages) 	2023 	2022 	2023 vs. 2022 	2023 	2022 	2023 vs. 2022
Three Months Ended
September 30,
Increase/
(Decrease)
Nine Months Ended
September 30,
Increase/
(Decrease)
UnitedHealthcare Employer & Individual — Domestic ... 	$ 	16,854 	$ 	15,929 	$ 	925 	6% $ 	50,157 	$ 	47,318 	$ 	2,839 	6%
UnitedHealthcare Employer & Individual — Global ...... 	2,417 	2,120 	297 	14 	6,905 	6,500 	405 	6
UnitedHealthcare Employer & Individual — Total .. 	19,271 	18,049 	1,222 	7 	57,062 	53,818 	3,244 	6
UnitedHealthcare Medicare & Retirement................... 	32,022 	27,895 	4,127 	15 	97,468 	85,620 	11,848 	14
UnitedHealthcare Community & State ....................... 	18,560 	16,051 	2,509 	16 	56,022 	47,257 	8,765 	19
Total UnitedHealthcare revenues........................ 	$ 	69,853 	$ 	61,995 	$ 7,858 	13% $ 210,552 	$ 186,695 	$ 23,857 	13%
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and
funding arrangement:
(in thousands, except percentages) 	2023 	2022 	2023 vs. 2022
September 30,
Increase/
(Decrease)
Commercial — Domestic:
Risk-based ......................................................................................................... 	8,120 	8,055 	65 	1%
Fee-based........................................................................................................... 	19,130 	18,500 	630 	3
Total Commercial — Domestic ............................................................................. 	27,250 	26,555 	695 	3
Medicare Advantage ................................................................................................ 	7,645 	7,035 	610 	9
Medicaid .............................................................................................................. 	8,065 	8,005 	60 	1
Medicare Supplement (Standardized) ............................................................................ 	4,345 	4,370 	(25) 	(1)
Total Community and Senior ................................................................................ 	20,055 	19,410 	645 	3
Total UnitedHealthcare — Domestic Medical ............................................................ 	47,305 	45,965 	1,340 	3
Commercial — Global .............................................................................................. 	5,475 	5,360 	115 	2
Total UnitedHealthcare — Medical ........................................................................ 	52,780 	51,325 	1,455 	3%
Supplemental Data:
Medicare Part D stand-alone................................................................................. 	3,335 	3,310 	25 	1%
UnitedHealthcare’s revenues increased due to growth in the number of people served through individual and group Medicare
Advantage plans; growth in people served with higher acuity needs partially offset by Medicaid redeterminations; and an
increase in the number of people served through commercial offerings. Earnings from operations increased due to increased
investment income and the factors impacting revenue, partially offset by elevated care activity, primarily relating to outpatient
care for seniors.
Optum
Total revenues and earnings from operations increased due to growth across the Optum businesses. The results by segment were
as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in patients served under value-based care arrangements
and business combinations. For the nine months ended September 30, 2023, earnings from operations increased, while
remaining consistent for the three months ended September 30, 2023, due to cost management initiatives and increased
investment income, offset by higher senior outpatient and behavioral health care activity, costs associated with serving newly
20

-- 22 of 29 --

added patients under value-based care arrangements and decreased asset dispositions. Optum Health served approximately
103 million people as of September 30, 2023 compared to 101 million people as of September 30, 2022.
Optum Insight
Revenues and earnings from operations at Optum Insight increased due to growth in business services as a result of business
combinations and growth in technology services.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to growth in pharmacy offerings and higher script volumes
from both new clients and growth in existing clients. Earnings from operations also increased as a result of continued supply
chain and operating cost management initiatives. Optum Rx fulfilled 383 million and 359 million adjusted scripts in the third
quarters of 2023 and 2022, respectively.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
(in millions) 	2023 	2022 	2023 vs. 2022
Nine Months Ended
September 30, Increase/
(Decrease)
Sources of cash:
Cash provided by operating activities ........................................................ 	$ 	34,261 	$ 	30,739 	$ 	3,522
Issuances of short-term borrowings and long-term debt, net of repayments ........... 	5,848 	3,806 	2,042
Proceeds from common stock issuances ..................................................... 	1,039 	1,084 	(45)
Customer funds administered .................................................................. 	2,037 	7,028 	(4,991)
Other ............................................................................................... 	— 	50 	(50)
Total sources of cash .................................................................................. 	43,185 	42,707
Uses of cash:
Common stock repurchases .................................................................... 	(6,500) 	(6,000) 	(500)
Cash paid for acquisitions, net of cash assumed ............................................ 	(8,389) 	(7,154) 	(1,235)
Purchases of investments, net of sales and maturities ..................................... 	(2,850) 	(4,067) 	1,217
Purchases of property, equipment and capitalized software .............................. 	(2,427) 	(1,936) 	(491)
Cash dividends paid ............................................................................. 	(5,023) 	(4,450) 	(573)
Other ............................................................................................... 	(2,495) 	(1,634) 	(861)
Total uses of cash ...................................................................................... 	(27,684) 	(25,241)
Effect of exchange rate changes on cash and cash equivalents................................. 	49 	4 	45
Net increase in cash and cash equivalents ......................................................... 	$ 	15,550 	$ 	17,470 	$ 	(1,920)
2023 Cash Flows Compared to 2022 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings and the receipt of our
October CMS premium payment of $11.9 billion and $9.8 billion in September 2023 and 2022, respectively. Other significant
changes in sources or uses of cash year-over-year included increased net issuances of short-term borrowings and long-term debt
and decreased net purchases of investments, partially offset by decreased customer funds administered, primarily driven by
Medicare Part D timing, and increased cash paid for acquisitions.
21

-- 23 of 29 --

Financial Condition
As of September 30, 2023, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of
$87.5 billion included approximately $38.9 billion of cash and cash equivalents (of which $1.5 billion was available for general
corporate use), $44.4 billion of debt securities and $4.2 billion of investments in equity securities. Given the significant portion
of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial
assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a
weighted-average duration of 3.8 years and a weighted-average credit rating of “Double A” as of September 30, 2023. When
multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the
weighted-average credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2022 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2022 10-K. During the nine
months ended September 30, 2023, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the
Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated
Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2022 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to
debt-plus-shareholders’ equity ratio of not more than 60%. As of September 30, 2023, our debt to debt-plus-shareholders’ equity
ratio, as defined and calculated under the credit facilities, was approximately 38%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of
this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2022 10-K.
Credit Ratings. Our credit ratings as of September 30, 2023 were as follows:
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Moody’s 	S&P Global 	Fitch 	A.M. Best
Senior unsecured debt......................................... 	A2 	Stable 	A+ 	Stable 	A 	Stable 	A 	Stable
Commercial paper ............................................. 	P-1 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1+ 	n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the nine months ended September 30, 2023, we repurchased approximately 13 million
shares at an average price of $485.10 per share. As of September 30, 2023, we had Board of Directors’ authorization to
purchase up to 18 million shares of our common stock.
22

-- 24 of 29 --

Dividends. In June 2023, the Company’s Board of Directors increased our quarterly cash dividend to shareholders to an annual
rate of $7.52 compared to $6.60 per share. For more information on our dividend, see Note 6 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Acquisitions. As of September 30, 2023, we have entered into agreements to acquire companies in the health care
sector, subject to regulatory approval and other customary closing conditions. The total anticipated consideration required for
these acquisitions, excluding the payoff of acquired indebtedness, is approximately $5 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” included in Part II, Item 7 in our 2022 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting
estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II,
Item 7 in our 2022 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated
Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2022 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending
on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or
changes in existing health care laws or regulations, or their enforcement or application; reductions in revenue or delays to cash
flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk
adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to
maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information
systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our
failure to comply with related regulations; risks and uncertainties associated with our businesses providing pharmacy care
services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our
public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and
maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of
potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government
investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risks associated with public
health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to
attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance;
impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related
23

-- 25 of 29 --

products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from
external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly
dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial
condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.
By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,
uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations
expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-
looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of September 30, 2023 on our investment income and interest expense per annum, and the fair value of
our investments and debt (in millions, except percentages):
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum
Interest
Expense Per
Annum
Fair Value of
Financial Assets
Fair Value of
Financial Liabilities
September 30, 2023
2%...................................................................................... 	$ 	971 	$ 	419 	$ 	(3,408) 	$ 	(7,067)
1 ........................................................................................ 	486 	209 	(1,758) 	(3,846)
(1) ...................................................................................... 	(486) 	(193) 	1,858 	4,635
(2) ...................................................................................... 	(971) 	(386) 	3,800 	10,274
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on
the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of September 30, 2023. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
September 30, 2023.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2023 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
24

-- 26 of 29 --

PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. 	RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I,
Item 1A, “Risk Factors” of our 2022 10-K, which could materially affect our business, financial condition or future results. The
risks described in our 2022 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or
that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2022 10-K.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF
EQUITY SECURITIES
Issuer Purchases of Equity Securities (a)
Third Quarter 2023
For the Month Ended
Total Number of
Shares Purchased
Average Price Paid
Per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares That May Yet Be
Purchased Under The
Plans or Programs
(in millions) 	(in millions) 	(in millions)
July 31, 2023 ....................................... 	1.2 	$ 	481.19 	1.2 	19.6
August 31, 2023.................................... 	1.0 	501.09 	1.0 	18.6
September 30, 2023 ............................... 	0.9 	488.62 	0.9 	17.7
Total.................................................. 	3.1 	$ 	489.56 	3.1
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2018, the
Board of Directors renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open market
purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.
ITEM 5. 	OTHER INFORMATION
Trading Arrangements
During the quarter ended September 30, 2023, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under
the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities
intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading
arrangement.
25

-- 27 of 29 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company’s
Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to
Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on February 26, 2021)
4.1 	Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and Wilmington Trust
Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on
Form 8-K filed on April 28, 2023)
4.2 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association
(incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, SEC File Number 333-149031,
filed on February 4, 2008)
4.3 	Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank Trust Company,
National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to
UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April 24, 2023)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are
embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term
debt are not filed. The Company will furnish copies thereof to the SEC upon request.
26

-- 28 of 29 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/S / ANDREW W ITTY
Andrew Witty
Chief Executive Officer
(principal executive officer)
Dated: 	November 6, 2023
/S / JOHN REX
John Rex
Executive Vice President and
Chief Financial Officer
(principal financial officer)
Dated: 	November 6, 2023
/S / T HOMAS ROOS
Thomas Roos
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: 	November 6, 2023
27

-- 29 of 29 --